Israel Stocks: Protalix, Biocell, Ceragon, Delta-Galil, Medigus
Israel’s TA-25 index slid to its lowest in more than a week, declining 0.7 percent to 1,158.65 at the 4:30 p.m. close in Tel Aviv. Investors traded about 1 billion shekels ($264 million) of shares and convertible securities, according to bourse data.
The following stocks rose or fell today. Symbols are in parentheses.
Can-Fite Biopharma Ltd. (CFBI) dropped 3.9 percent to 0.394 shekel, the lowest level since April 18. The Petach Tikva, Israel-based biopharmaceutical company raised about 5.8 million shekels from a public offering of securities.
Ceragon Networks Ltd. (CRNT) advanced 1.9 percent to 35.97 shekels, the highest close since April 18. The maker of wireless-networking systems won orders for high-capacity wireless products from the Florida Rural Broadband Alliance.
Delta-Galil Industries Ltd. (DELT) advanced 6 percent to 32.62 shekels, the highest since January 2011. The manufacturer of intimate apparel signed an accord to buy Schiesser Group AG for 68 million euros ($89 million).
Intec Pharma Ltd. (INTP) retreated 4.9 percent, the most since Dec. 27, to 0.982 shekel giving the company a market value of 181 million shekels. The drug developer plans to raise 15 million shekels via a rights offering.
Medigus Ltd. (MDGS) gained 3.5 percent, the most since April 30, to 1.063 shekels. The developer of endoscopic procedures and devices expects a decision in the “near future” by the U.S. Food and Drug Administration on an application to market its SRS device to treat gastroesophageal-reflux disease.
Protalix BioTherapeutics Inc. (PLX) surged 14 percent to 29.14 shekels, the highest since February 2011. The biopharmaceutical company’s debut drug won approval from the U.S. Food and Drug Administration. Biocell Ltd. (BCEL) , Protalix’s largest shareholder, jumped the most since January 2009, advancing 26 percent to 34.87 shekels.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.